Publicación:
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?

Vista sencilla de ítem
dc.contributor.authorSantos Moreno, Pedro
dc.contributor.authorBuitrago García, Diana
dc.contributor.authorVillarreal, Laura
dc.contributor.authorAza, Anggie
dc.contributor.authorCabrera, Michael
dc.contributor.authorRivero, Wilberto
dc.contributor.authorRojas Villarraga, Adriana
dc.date.accessioned2021-10-13T14:15:11Z
dc.date.available2021-10-13T14:15:11Z
dc.date.issued2020-06-24
dc.description.abstractWe read with interest the paper of Graef et al recently published in your journal about the situation resulting from the massive use of antimalarials for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19), despite the fact that the evidence is controversial and there are concerns about its possible cardiotoxicity, leaving rheumatic patients who use them in a position of vulnerability due to medication shortages.1 In the past few weeks, several papers have been published about the efficacy and safety of the antimalarials chloroquine (CLQ) and hydroxychloroquine (HCLQ) for the treatment of the different phases of infection by SARS-CoV-2/COVID-19, and the data are controversial. However, it is striking that some studies report high rates of cardiovascular events (CVEs) associated mainly with cardiac arrhythmias.2 . These findings of adverse CVEs reported in the aforementioned studies have unfortunately led to the emergency in this group of patients around fear of chronic use of antimalarials, and many users are abandoning these medications, which implies great clinical risk due to relapses that may appear.3 On the other hand, the massive use of antimalarials for COVID-19 has resulted in medication shortages in some settings with potential consequences to patients users. Antimalarials have been used for several decades for the treatment of malaria and some autoimmune diseases, mainly rheumatoid arthritis (RA) and lupus, with great utility and efficacy, and also great safety at conventional doses (250mg per day of CLQ and 200–400mg per day of HCLQ).eng
dc.format.extent2 p.spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.urihttps://repositorio.fucsalud.edu.co/handle/001/1848
dc.language.isoengspa
dc.publisherAlianza Europea de Asociaciones de Reumatología (EULAR) y BMJspa
dc.publisher.placeReino Unidospa
dc.relation.citationendpage2spa
dc.relation.citationissue0spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume0spa
dc.relation.ispartofAnnals of the Rheumatic Diseases e-ISSN:1468-2060 Mes: 7 (2020)
dc.relation.ispartofjournalAnnals of the Rheumatic Diseasesspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nd/4.0/spa
dc.sourcehttps://ard.bmj.com/content/early/2020/07/08/annrheumdis-2020-218259spa
dc.subject.decsEnfermedades cardiovasculares
dc.subject.decsEfectos colaterales y reacciones adversas relacionados con medicamentos
dc.subject.lembAntimalaricos
dc.subject.proposalEnfermedad cardiovascularspa
dc.subject.proposalArtritis reumatoidespa
dc.subject.proposalEventos adversosspa
dc.subject.proposalReacciones a los antipalúdicosspa
dc.subject.proposalCOVID-19spa
dc.titleEmergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?eng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttps://purl.org/redcol/resource_type/WPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times, are antimalarials as unsafe for cardiovascular health as recent reports suggest.pdf
Tamaño:
125.8 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
15.06 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos